Sherman Spotlights Advances With RET Inhibitors in Medullary Thyroid Cancer

Season 5 Episode 20  ·  Jul 01, 2021, 06:45 PM

Headliner
Share
Subscribe

Dr. Sherman discusses the incidence of RET fusions in medullary thyroid cancer and the current clinical landscape of RET inhibitors in the field.

Share
Subscribe
Next
Research Reflections: O'Malley Relays Key Updates in Ovarian and Endometrial Cancers
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air